Furthermore, a higher percentage of glioma patients was significantly positive for MMP-9, MMP-9/NGAL, and MMP-9 Dimer activity, compared with control patients (Figure 1(b), p < 0.01). This evidence concerns the gene MMP9 and central nervous system cancer.